Vertos Medical

Vertos Medical, Inc. Ranked Number 370 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™

Retrieved on: 
Wednesday, November 8, 2023

ALISO VIEJO, Calif., Nov. 8, 2023 /PRNewswire/ -- Vertos Medical today announced it ranked 370 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29th year. Vertos Medical grew 343% between 2019 and 2022.

Key Points: 
  • Attributes the company's remarkable 343% revenue growth to its innovation and unwavering commitment to enhancing the quality of patients' lives.
  • ALISO VIEJO, Calif., Nov. 8, 2023 /PRNewswire/ -- Vertos Medical today announced it ranked 370 on the Deloitte Technology Fast 500 ™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29th year.
  • Wichems said, "We're honored to receive recognition for a second year in a row as one of North America's fastest-growing companies.
  • Vertos Medical previously ranked 384 as a Technology Fast 500 award winner for 2022.

Vertos Medical Promotes Two Senior Leaders to Newly Created C-Suite Roles

Retrieved on: 
Tuesday, August 15, 2023

ALISO VIEJO, Calif., Aug. 15, 2023 /PRNewswire/ -- Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for lumbar spinal stenosis (LSS), announced today that its Vice President of Sales, Stephen E. Paul, has been named chief commercial officer (CCO), and its Vice President of Research and Development, Mehrzad Khakpour, Ph.D., has been named chief technology officer (CTO) for the rapidly growing company. The promotions come on the heels of a recent Series C equity funding round of more than $26 million.

Key Points: 
  • The promotions come on the heels of a recent Series C equity funding round of more than $26 million.
  • Vertos Medical's proprietary technology, the mild® Procedure, has been shown in many studies to help restore mobility and decrease pain for LSS patients while greatly improving their quality of life.
  • Dr. Khakpour, previously Vertos' vice president of research and development, also boasts more than 20 years of experience in medical device research and innovation, with numerous notable past accomplishments.
  • In his newly created CTO position, he will oversee Vertos' upstream marketing, R&D, and clinical research teams to steer the company toward promising adjunctive innovations.

Vertos Medical Appoints New Vice President of R&D

Retrieved on: 
Monday, November 21, 2022

ALISO VIEJO, Calif., Nov. 21, 2022 /PRNewswire/ -- Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for lumbar spinal stenosis (LSS), today announced the appointment of Mehrzad Khakpour, PhD as Vice President of Research and Development. Dr. Khakpour will be responsible for directing all aspects of research and development for the company.

Key Points: 
  • ALISO VIEJO, Calif., Nov. 21, 2022 /PRNewswire/ -- Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for lumbar spinal stenosis (LSS), today announced the appointment of Mehrzad Khakpour, PhD as Vice President of Research and Development.
  • Dr. Khakpour brings a wealth of both technological innovation and product development experience to his role at Vertos, in addition to extensive medical device experience from inception to IPO.
  • "Mehrzad joins the Vertos team at a pivotal time of growth and transformation as we continue to evolve the mild Procedureand also look to expand treatment options for patients suffering from back pain," said Eric Wichems, President and CEO of Vertos Medical.
  • Vertos Medical is an interventional pain company committed to developing innovative, minimally invasive treatments for lumbar spinal stenosis (LSS).

Vertos Medical, Inc. Ranked Number 384 Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™

Retrieved on: 
Wednesday, November 16, 2022

ALISO VIEJO, Calif., Nov. 16, 2022 /PRNewswire/ -- Vertos Medical today announced it ranked 384 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 28th year. Vertos Medical grew 348% between 2018 and 2021.

Key Points: 
  • ALISO VIEJO, Calif., Nov. 16, 2022 /PRNewswire/ -- Vertos Medical today announced it ranked 384 on the Deloitte Technology Fast 500 , a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 28th year.
  • He said, "We are thrilled to be recognized as one of the fastest growing companies in North America.
  • Overall, 2022 Technology Fast 500 companies achieved revenue growth ranging from 241% to 125,138% from 2018 to 2021, with median growth of 611%.
  • Now in its 28th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies both public and private in North America.

CAN Health Network Provides National Access to Verto's Canadian-Made Digital Twin Technology

Retrieved on: 
Thursday, October 6, 2022

Verto's Digital Twin Orchestration technology connects relevant pieces of information about patients across any IT system to build complex, dynamic profiles of each individual.

Key Points: 
  • Verto's Digital Twin Orchestration technology connects relevant pieces of information about patients across any IT system to build complex, dynamic profiles of each individual.
  • In 2020, Unity Health joined the CAN Health Network and launched a commercialization project with Verto to develop and implement a global consent model with a focus on digital communications.
  • "This is what the Network is all about validating Canadian technology solutions and making it easier for healthcare organizations to procure them," said Dante Morra, Chair, CAN Health Network.
  • Verto Inc. is a rapidly growing Canadian digital health company offering a Digital Twin Orchestration Platform.

Verto Launches B2B Multi-Currency Global Account Solutions

Retrieved on: 
Wednesday, May 25, 2022

Verto , the leading B2B cross-border foreign exchange (FX) and payments enabler, today announced the launch of its multi-currency global account.

Key Points: 
  • Verto , the leading B2B cross-border foreign exchange (FX) and payments enabler, today announced the launch of its multi-currency global account.
  • The global account is a channel for businesses, regardless of where they are based, to access effective multi-currency solutions without the need for a local entity.
  • With our Global Account solutions, we now support businesses and merchants across the UK, US, Europe and emerging markets who need access to foreign account capabilities in neighbouring countries for regional and global expansion, commented Ola Oyetayo, CEO and Co-Founder of Verto.
  • Our new Global Account solutions give businesses innovative multi-currency services on the receiving end, strengthening Vertos pay-in capabilities.

AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors

Retrieved on: 
Tuesday, June 1, 2021

During his career he has served as CEO of 3 publicly listed companies; Microtherapeutics Inc (MTIX), ev3 Inc (evvv), Alphatec Spine (ATEC).

Key Points: 
  • During his career he has served as CEO of 3 publicly listed companies; Microtherapeutics Inc (MTIX), ev3 Inc (evvv), Alphatec Spine (ATEC).
  • Mr. Corbett has also led two privately funded companies as CEO; Home Diagnostics Inc. and Vertos Medical.
  • We are delighted by the addition of James and Jan to our Board of Directors.
  • They will further strengthen our Board, bringing extensive medical device commercialization, legal and strategic business expertise to Avita, said Lou Panaccio, Chairman of the Board of Avita Medical.

Vertos Medical Announces ASC Reimbursement Increase for the mild® Procedure

Retrieved on: 
Tuesday, December 8, 2020

Effective January 1, 2021, the national average ASC reimbursement for CPT 0275T will increase by 41%, from $2,803.35 to $3,941.14, in recognition of the device cost associated with the procedure.

Key Points: 
  • Effective January 1, 2021, the national average ASC reimbursement for CPT 0275T will increase by 41%, from $2,803.35 to $3,941.14, in recognition of the device cost associated with the procedure.
  • "The mild Procedure is ideally suited for an ASC setting and we are pleased that CMS has improved the reimbursement for these facilities.
  • We believe this will significantly increase patient access to the mild Procedure across the country," said Philip Macdonald, Vice President, Market Access & Reimbursement for Vertos Medical.
  • Vertos Medical Inc. is a medical device company committed to developing innovative, minimally invasive treatments for lumbar spinal stenosis (LSS).

Vertos Medical Completes Enrollment in MOTION Study of mild® Procedure, a Minimally Invasive Treatment for Lumbar Spinal Stenosis

Retrieved on: 
Tuesday, December 3, 2019

ALISO VIEJO, Calif., Dec. 3, 2019 /PRNewswire/ -- Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for lumbar spinal stenosis (LSS), today announced the completion of enrollment in its nationwide, multicenter MOTION Study of its mild Procedure.

Key Points: 
  • ALISO VIEJO, Calif., Dec. 3, 2019 /PRNewswire/ -- Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for lumbar spinal stenosis (LSS), today announced the completion of enrollment in its nationwide, multicenter MOTION Study of its mild Procedure.
  • It is the second large, multi-center study, randomized controlled trial that has been done on the mild Procedure.
  • The mild Procedure is a clinically proven outpatient LSS treatment that removes the cause of stenosis through a portal the size of a baby aspirin.
  • Vertos Medical Inc. is a medical device company committed to developing innovative, minimally invasive treatments for lumbar spinal stenosis (LSS).

Vertos Medical Appoints New Vice President of Sales

Retrieved on: 
Tuesday, August 6, 2019

ALISO VIEJO, Calif., Aug. 6, 2019 /PRNewswire/ -- Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for lumbar spinal stenosis (LSS), today announced the appointment of Stephen E. Paul as Vice President of Sales.

Key Points: 
  • ALISO VIEJO, Calif., Aug. 6, 2019 /PRNewswire/ -- Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for lumbar spinal stenosis (LSS), today announced the appointment of Stephen E. Paul as Vice President of Sales.
  • He has worked for companies such as Boston Scientific, Masimo and most recently served as Vice President of Sales and Commercial Operations for Breg, a major manufacturer and distributor of orthopedic devices.
  • "Steve joins the Vertos leadership team at a pivotal time of growth as we see increased demand for the mildprocedureas a treatment option for millions who suffer from LSS," said Eric Wichems, President and CEO of Vertos Medical.
  • Vertos Medical Inc. is a medical device company committed to developing innovative, minimally invasive treatments for lumbar spinal stenosis (LSS).